Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2018
Novartis receives Health Canada approval for the combination therapy of Tafinlar (dabrafenib) plus Mekinist (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma
1 November 2018 - First approval in Canada of an adjuvant treatment for melanoma (BRAF V600 mutated). ...
Posted by Michael Wonder on 26 Oct 2018
Bayer receives approval for haemophilia A treatment Jivi
24 October 2018 - Extended half-life product that offers a reduction in dosing frequency and improved bleeding protection. ...
Posted by Michael Wonder on 18 Oct 2018
Health Canada has approved Invokana (canagliflozin) for reduction of major adverse cardiovascular events, the first SGLT2 inhibitor in Canada to receive this indication
17 October 2018 - Invokana has been shown to reduce the combined risk of cardiovascular death, non-fatal myocardial infarction and ...
Posted by Michael Wonder on 17 Oct 2018
Health Canada approves Xermelo (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea
16 October 2018 - Xermelo is a first-in-class treatment option for patients whose refractory carcinoid syndrome diarrhoea is inadequately controlled with ...
Posted by Michael Wonder on 09 Oct 2018
Health Canada approves new indications for Xeljanz in ulcerative colitis & psoriatic arthritis
9 October 2018 - Xeljanz, an oral therapy, is the first and only Janus kinase inhibitor approved by Health Canada for ...
Posted by Michael Wonder on 06 Oct 2018
AbbVie receives Health Canada approval of Orilissa (elagolix) for the treatment of moderate to severe pain associated with endometriosis
5 October 2018 - The approval of Orilissa is supported by data from two replicate Phase 3 studies, which evaluated nearly ...
Posted by Michael Wonder on 05 Oct 2018
Health Canada approves Radicava (edaravone) for the treatment of ALS
5 October 2018 - Mitsubishi Tanabe Pharma Corporation announced today that Edaravone (US name: Radicava; Japan name: Radicut bag for ...
Posted by Michael Wonder on 05 Oct 2018
Akcea and Ionis announce approval of Tegsedi (inotersen injection) in Canada
4 October 2018 - First and only treatment of its kind for Canadians with hereditary transthyretin-mediated amyloidosis with polyneuropathy – a ...
Posted by Michael Wonder on 02 Oct 2018
Health Canada approves Tresiba for children with Type 1 diabetes
1 October 2018 - Rates of Type 1 diabetes among children and youth on the rise globally. ...
Posted by Michael Wonder on 26 Sep 2018
AbbVie receives approval from Health Canada for the combination of Venclexta with rituximab as a treatment for patients with chronic lymphocytic leukaemia
25 September 2018 - In the MURANO Phase 3 clinical trial, the Venclexta (venetoclax) plus rituximab combination showed a significant improvement ...
Posted by Michael Wonder on 21 Sep 2018
Health Canada has authorised Takhyzro (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema attacks
20 September 2018 - New treatment option for HAE receives first international marketing authorization outside of the U.S. ...
Posted by Michael Wonder on 20 Sep 2018
Exelixis’ partner Ipsen announces Health Canada’s approval of Cabometyx (cabozantinib) tablets for the treatment of adults with previously treated advanced renal cell carcinoma
19 September 2018 - Approval based on the improvement in overall survival, progression-free survival and objective response rate for CABOMETYX versus ...
Posted by Michael Wonder on 19 Sep 2018
Sunovion announces Health Canada approval of Aptiom (eslicarbazepine acetate) as adjunctive therapy for the treatment of partial-onset seizures in adolescents and children above six years of age
19 September 2018 - Sunovion Pharmaceuticals today announced that Health Canada approved the supplemental new drug submission to expand the ...
Posted by Michael Wonder on 15 Sep 2018
Herceptin (trastuzumab) subcutaneous formulation approved in Canada for the treatment of HER2-positive breast cancer
13 September 2018 - Subcutaneous formulation takes two to five minutes to administer, rather than up to 90 minutes with the ...
Posted by Michael Wonder on 12 Sep 2018
Health Canada approves Merck's Stromectol (ivermectin) for the treatment of intestinal strongyloidiasis and onchocerciasis
11 September 2018 - The product's availability is expected in November 2018. ...